Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Part of paid clinical trials in Irvine, California.

Sponsor
BioAtla, Inc.
Study ID
NCT05808634
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BA3182 — DRUG
    Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM

Study Details

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

Key Dates

Start date
Jul 14, 2023
Status verified
Sep 2025
Primary completion
Sep 15, 2028
Completion
Sep 15, 2028

Study Design

Enrollment
168 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BA3182
    All Patients will receive BA3182

Primary Outcome Measure

Part 1: Assess dose limiting toxicity as defined in the protocol [ Time Frame: Up to 24 months ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
UC IrvineIrvineCalifornia92697
Chao Family Comprehensive Cancer Center
[email protected]
877-827-8839
USC Norris Comprehensive Cancer CenterLos AngelesCalifornia90033
Lorraine Martinez Seng
[email protected]
323-865-3000
Yale Cancer CenterNew HavenConnecticut06511
Ingrid Palma
[email protected]
203-833-1034
Northwestern UniversityChicagoIllinois60611
Clinical Research Office
[email protected]
312-695-1301
University of IllinoisChicagoIllinois60612
Omer Qazi
[email protected]
312-413-1069
Karmanos Cancer InstituteDetroitMichigan48201
Clarice Zuccaro
[email protected]
313-576-9375
The Christ Hospital Cancer CenterCincinnatiOhio45219
Abby Reed
[email protected]
513-585-0844
University Hospitals Cleveland Medical CenterClevelandOhio44106
Principal Investigator
[email protected]
216-844-3951
Fred Hutch Cancer CenterSeattleWashington98109
Phase 1 Clinical Trials
[email protected]
206-606-7551

Find similar trials in Irvine, CA

By research site
UC Irvine· Irvine, CAUSC Norris Comprehensive Cancer Center· Los Angeles, CAYale Cancer Center· New Haven, CTNorthwestern University· Chicago, ILUniversity of Illinois· Chicago, ILKarmanos Cancer Institute· Detroit, MI

Related Studies